Evidence map›Paper›PMID 22862891›Full record

ArticleBMC medical research methodology2012

Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies.

Sara Raimondi, Sara Gandini, Maria Concetta Fargnoli, Vincenzo Bagnardi, Patrick Maisonneuve, Claudia Specchia, Rajiv Kumar, Eduardo Nagore, Jiali Han, Johan Hansson and 28 more

Abstract read
In one paragraph

Article in BMC medical research methodology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Age-specific melanoma risk associated with melanocytic nevi: a pooled analysis from the M-SKIP project.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026
    Article
  2. Article
  3. Association of MC1R variants with melanoma risk and interaction with sun exposure: An M-SKIP project.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Article
  4. Extended two-stage designs for environmental research.Environmental health : a global access science source · 2022
    Article
  5. MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M-SKIP project.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021
    Article
  6. Article
  7. Melanoma Epidemiology and Sun Exposure.Acta dermato-venereologica · 2020
    Review
  8. Cancer management and research · 2018
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Sara RaimondiDivision of Epidemiology and Biostatistics, European Institute of Oncology, Via Ramusio 1, Milan, 20141, Italy. sara.raimondi@ieo.it
Sara Gandini
Maria Concetta Fargnoli
Vincenzo Bagnardi
Patrick Maisonneuve
Claudia Specchia
Rajiv Kumar
Eduardo Nagore
Jiali Han
Johan Hansson
Peter A Kanetsky
Paola Ghiorzo
Nelleke A Gruis
Terry Dwyer
Leigh Blizzard
Ricardo Fernandez-de-Misa
Wojciech Branicki
Tadeusz Debniak
Niels Morling
Maria Teresa Landi
Giuseppe Palmieri
Gloria Ribas
Alexander Stratigos
Lynn Cornelius
Tomonori Motokawa
Sumiko Anno
Per Helsing
Terence H Wong
Philippe Autier
José C García-Borrón
Julian Little
Julia Newton-Bishop
Francesco Sera
Fan Liu
Manfred Kayser
Tamar Nijsten
GEM Study Group
M-SKIP Study Group

Funding

Melanoma RAS/BRAF Mutation:Heterogeneity-Risk-PrognosisR01CA112243 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMAS, NANCY E. · 2005 to 2014
$5.4M
Cancer Research UK 10589NCI NIH HHS CA112243-05 S1NCI NIH HHS R01 CA112243
6 · The paper itself

Abstract

backgroundFor complex diseases like cancer, pooled-analysis of individual data represents a powerful tool to investigate the joint contribution of genetic, phenotypic and environmental factors to the development of a disease. Pooled-analysis of epidemiological studies has many advantages over meta-analysis, and preliminary results may be obtained faster and with lower costs than with prospective consortia. DESIGN AND

methodsBased on our experience with the study design of the Melanocortin-1 receptor (MC1R) gene, SKin cancer and Phenotypic characteristics (M-SKIP) project, we describe the most important steps in planning and conducting a pooled-analysis of genetic epidemiological studies. We then present the statistical analysis plan that we are going to apply, giving particular attention to methods of analysis recently proposed to account for between-study heterogeneity and to explore the joint contribution of genetic, phenotypic and environmental factors in the development of a disease. Within the M-SKIP project, data on 10,959 skin cancer cases and 14,785 controls from 31 international investigators were checked for quality and recoded for standardization. We first proposed to fit the aggregated data with random-effects logistic regression models. However, for the M-SKIP project, a two-stage analysis will be preferred to overcome the problem regarding the availability of different study covariates. The joint contribution of MC1R variants and phenotypic characteristics to skin cancer development will be studied via logic regression modeling. DISCUSSION: Methodological guidelines to correctly design and conduct pooled-analyses are needed to facilitate application of such methods, thus providing a better summary of the actual findings on specific fields.

Indexed as

Epidemiologic Research DesignGenetic Predisposition to DiseaseReceptor, Melanocortin, Type 1AdultCase-Control StudiesData CollectionData Interpretation, StatisticalFemaleHospitalizationHumansLogistic ModelsMaleMeta-Analysis as TopicPhenotypeSkin NeoplasmsSmokingReceptor, Melanocortin, Type 1

Identifiers

PMID22862891
PMCPMC3502117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.